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Summary
Studies on Caenorhabditis elegans have provided detailed
insight into host-pathogen interactions [1–7]. Usually, the
E. coli strain OP50 is used as food source for laboratory
studies, but recent work has shown that a variety of bacteria
have dramatic effects on C. elegans physiology, including
immune responses [8–18]. However, the mechanisms by
which different bacteria impact worm resistance to patho-
gens are poorly understood. Although pathogen-specific im-
mune priming is often discussed as amechanismunderlying
such observations [13, 14], interspecies microbial antago-
nism might represent an alternative mode of action. Here,
we use several natural Bacillus strains to study their effects
on nematode survival upon pathogen challenge. We show
that B. subtilis GS67 persists in the C. elegans intestine
and increases worm resistance to Gram-positive pathogens,
suggesting that direct inhibition of pathogens might be
the primary protective mechanism. Indeed, chemical and ge-
netic analyses identified the lipopeptide fengycin as the ma-
jor inhibitory molecule produced byB. subtilisGS67. Specif-
ically, a fengycin-defective mutant of B. subtilis GS67 lost
inhibitory activity against pathogens and was unable to pro-
tect C. elegans from infections. Furthermore, we found that
purified fengycin cures infected worms in a dose-dependent
manner, indicating that it acts as an antibiotic. Our results
reveal a molecular mechanism for commensal-mediated
C. elegans protection and highlight the importance of inter-
species microbial antagonism for the outcome of animal-
pathogen interactions. Furthermore, our work strengthens
C. elegans as an in vivo model to reveal protective mecha-
nisms of commensal bacteria, including those relevant to
mammalian hosts.Results and Discussion
A previous systematic analysis of Bacillus strains isolated from
different sources revealed that the majority of strains were
benign to the twomodelnematodesC.elegansandPristionchus
pacificus [19]. However, we also discovered B. thuringiensis
DB27, a highly virulent pathogen that kills C. elegans in less
than 16 hr [20]. Subsequently, we have shown the C. elegans
defense mechanisms against this strain to involve dcr-1/dicer
[21] and have identified two new pore-forming toxins as3Present address: Global Health Institute, School of Life Sciences, E´cole
Polytechnique Fe´de´rale de Lausanne (EPFL), 1015 Lausanne, Switzerland
*Correspondence: ralf.sommer@tuebingen.mpg.debacterial virulence factors [20, 22], revealing additional impor-
tant components of extensively studied C. elegans response
to B. thuringiensis pore-forming toxins [23–29].
A number of studies have shown that different bacteria
have dramatic effects on C. elegans immune responses [8–
18], with pathogen-specific immune priming often being dis-
cussed as an underlying mechanism [13, 14]. To test whether
naturally isolated bacteria have an effect on worm resistance
to B. thuringiensis DB27, we selected from our library [19]
several nonpathogenic strains of different Bacillus species
that are often found in the natural habitat of C. elegans [9,
14] and tested whether feeding on those strains has an effect
on C. elegans survival (Figure 1A). Indeed, we found that
preincubation with nine strains of Bacillus resulted in sig-
nificant levels (20%–50%) of worm protection (p % 0.05)
compared to E. coli OP50 (Figure 1B). Out of all tested strains,
B. subtilis GS67 showed the strongest effect on C. elegans,
with up to 50% survival after 16 hr postinfection and with an
average survival of up to 3 days (Figure 1C). These results
demonstrate that natural Bacillus isolates have an effect on
C. elegans response to pathogens. To investigate the under-
lying molecular mechanisms, we concentrated on B. subtilis
GS67.
First, we asked whether the observed effect of B. subtilis
GS67 is specific to B. thuringiensis DB27 or whether the nem-
atodes acquire resistance to other pathogens as well. Upon
exposure of worms precultured on B. subtilis GS67 to another
Gram-positive pathogen, Staphylococcus aureus, we again
observed significant (p % 0.001) increase of survival as
compared to worms precultured on E. coli OP50 (Figure 1D).
In contrast, when we tested survival on two Gram-negative
pathogens S. marcescens (Figure 1E) and P. aeruginosa (Fig-
ure 1F), we found no differences in survival between worms
precultured on either B. subtilis GS67 or E. coli OP50. Thus,
B. subtilis GS67 increases C. elegans resistance to a group
of Gram-positive pathogens but has no effect on resistance
to the tested Gram-negative bacteria.
We noticed that C. elegans grown on B. subtilis GS67 accu-
mulated large amounts of Bacillus spores and cells in the in-
testine (Figure 2A). To estimate the period of persistence of
B. subtilis GS67 in the C. elegans gut, we transferred GS67-
grown worms to OP50 and determined colony-forming units
(cfu) of B. subtilis GS67 after defined time intervals. Even
24 hr after transfer, we could still isolate GS67 from nematodes
(Figure 2B), indicating thatB. subtilisGS67 can persist for long
times in the C. elegans gut. We therefore hypothesized that
B. subtilis GS67 might provide protection to C. elegans via
direct inhibition of B. thuringiensis DB27 and other Gram-pos-
itive pathogens. To test this hypothesis, we employed a
simple disc-diffusion inhibition assay. Indeed, we found that
supernatant of B. subtilis GS67 strongly inhibits growth of
B. thuringiensis DB27 (Figure 2C). We further confirmed the
antagonistic properties of GS67 in coculture experiments.
When B. subtilis GS67 and B. thuringiensis DB27 were coino-
culated at equal doses, B. thuringiensis DB27 was completely
eliminated after 24 hr of culturing (Figure 2D). Even when
B. thuringiensis DB27 was inoculated with a dose twice as
high as B. subtilis GS67, B. thuringiensis DB27 was still
Figure 1. C. elegans Grown on Nonpathogenic Bacillus Is More Resistant to Gram-Positive Pathogens
(A) Scheme of C. elegans feeding assay with Bacillus. Eggs obtained by the bleaching of worms grown on OP50 were put on plates with naturally isolated
Bacillus and allowed to develop until adulthood. Adults were transferred to plateswith pathogenicB. thuringiensisDB27, and survival was scored 16 hr later.
(B) C. elegans survival on a pathogenic B. thuringiensis DB27 after feeding on different Bacillus strains. Survival was scored 16 hr after infection.
Error bars represent 6SEM. Statistically significant values (*p < 0.05) compared to E.coli OP50 were determined with one-way ANOVA and Tukey’s post
hoc test.
(C) Worms grown on B. subtilis GS67 survive on B. thuringiensis DB27 up to three times longer compared to OP50-grown counterparts (p < 0.0001).
(D–F) B. subtilis GS67 sighificantly (p < 0.001) increases C. elegans survival on S. aureus, but not on Gram-negative pathogens S. marcescens (E) and
P. aeruginosa (F). Error bars represent 6SEM.
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in growth rates because in the absence of antagonists, both
cultures reach the same cell density (Figure 2D). When we
investigated the spectrum of B. subtilis GS67 antagonistic ac-
tivity, exposing several Gram-positive and Gram-negative
bacteria to B. subtilisGS67 supernatant, we found that several
Gram-positive bacteria, including different Bacillus species
and S. aureus, were strongly inhibited by B. subtilisGS67 (Fig-
ure 2E). In contrast, all tested Gram-negative species were
resistant to B. subtilis GS67 inhibition. Thus, B. subtilis GS67
specifically inhibits Gram-positive bacteria, a finding that isin line with the protective effect of B. subtilis GS67 against
Gram-positive pathogens on C. elegans.
To provide direct evidence that the bacterial antagonism
observed in vitro contributes to C. elegans protection in vivo,
we first estimated colonization of the C. elegans intestine
by B. thuringiensis DB27. For this, worms were grown on
OP50 (control), on B. subtilis GS67 (antagonist of DB27), or
on B. subtilis 1A699 (a strain without antagonistic activity)
and were subsequently infected with B. thuringiensis DB27.
Worms grown on B. subtilis GS67 showed significant reduced
pathogen accumulation in their intestines, as determined by
Figure 2. B. subtilis GS67 Persists in C. elegans Intestine and Inhibits B. thuringiensis DB27
(A) Nematodes grown on B. subtilis GS67 accumulate a large amount of bacterial cells and spores (white arrow) in the intestine. The scale bar represents
20 mm.
(B) Worms transferred from B. subtilis GS67 to OP50 carry viable B. subtilis GS67 cells in the intestine up to 24 hr. Ten worms in three replicates were
analyzed for each time point. Error bars represent 6SEM.
(C) Representative image of disc-diffusion assay showing that cell-free supernatant of B. subtilis GS67 inhibits B. thuringiensis DB27 in contrast to control,
where LB medium was used. Size of the inhibition zone is approximately 17 mm.
(D) B. subtilis GS67 inhibits B. thuringiensis DB27 in coculture experiment. B. thuringiensis DB27 is completely eliminated after 24 hr of coculture with
B. subtilis GS67, when inoculated at equal (1:1) or two times higher (1:2) dose. GS67 and DB27 alone exhibit similar (p > 0.05) growth rates. Growth of
GS67 is significantly (p = 0.011) reduced only when DB27 is present at two times higher (1:2) dose, but not at equal (1:1) dose (p > 0.05). Error bars represent
6SEM.
(E) Spectrum ofB. subtilisGS67antagonistic activity determined by disc-diffusion assay. Multiple strains of each species were tested. Results for represen-
tative strain of each species are shown. Differences between Bacillus species are not significant (p > 0.05, ANOVA, and Tukey’s post hoc test). Error bars
represent 6SEM.
(F) B. thuringiensis DB27 colonization of C. elegans intestine. Worms grown on OP50, GS67 (antagonist of DB27), and 1A699 (nonantagonist of DB27) were
infected with B. thuringiensis DB27 for 4 hr, and DB27 cfu were determined for each case. Ten worms in three replicates were used for each tested group.
GS67 significantly (p < 0.0001) reduces number of DB27 cfu compared to OP50 or 1A699. Error bars represent 6SEM.
(G) Curing of DB27-infected nematodes. Worms (n = 50 in three replicates for each treatment) infected with DB27 for 4 hr were transferred to OP50 plates
pretreated with supernatants of GS67 or 1A699 and scored for survival over time. GS67 curing effect is significant (p < 0.0001) compared to 1A699 or
no-treatment control. Shown are representative results of at least two independent experiments.
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1A699 accumulated high amounts of B. thuringiensis DB27,
similar to OP50-grown worms (Figure 2F). These resultssuggest that the B. subtilis GS67 antagonistic properties
can reduce colonization of C. elegans intestine by the
pathogen.
Figure 3. Identification of Inhibitory Molecule
(A) Cell-free supernatant ofB. subtilisGS67was subjected to heat (100C for
1 h) or enzymatic treatment (final enzyme concentration: 1 mg/ml, for 1 hr at
37C) and tested for the remaining activity in the disc-diffusion assay. Pro-
teinase K (p < 0.01), trypsin, protease, and lipase (p < 0.0001) significantly
reduce antimicrobial activity.
(B) Structures of fengycins A and B. Characteristic fragmentation patterns in
ESI+-MS are shown. [M+H]+ values are shown in black, and [M +Na]+ values
are shown in gray.
See also Figure S1.
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from an already existing B. thuringiensis DB27 infection.
Worms grown on OP50 were infected with B. thuringiensis
DB27 and then treated withB. subtilis supernatants. Strikingly,
nearly 80% of the worms treated with B. subtilis GS67 super-
natant remained alive after 24 hr (Figure 2G) and then exhibited
normal lifespan, as if they were never infected (Figure 2G), indi-
cating that B. subtilis GS67 can completely rescue infected
worms. In contrast, untreated worms and worms treated
with B. subtilis 1A699 supernatant mostly died 24 hr posttreat-
ment (Figure 2G). These results suggest that B. subtilis GS67
produces a factor, for example, a small molecule, with specific
activity against B. thuringiensis DB27 and possibly other
Gram-positive bacteria.
To identify the biochemical nature of the putative inhibitory
molecule, cell-free supernatant of B. subtilisGS67 was treated
with different enzymes and tested for remaining activity. Treat-
ment with trypsin, protease, and lipase completely eliminated
the antagonistic activity, suggesting that a lipopeptide was
involved in the inhibition (Figure 3A). Heat stability (Figure 3A)
and activity against closely related bacteria (Figure 2E) sug-
gest that this lipopeptide acts similarly to classical bacterio-
cins, known proteinaceous compounds produced by bacteria
to kill closely related species [30].To identify the inhibitory molecule, we fractionated metabo-
lite extract from 6 l of B. subtilis GS67 culture, using the
disc-diffusion inhibition assay to monitor activity. This led to
isolation of 12 mg of active material that appeared to repre-
sent a mixture of lipopeptides, based on initial nuclear mag-
netic resonance-spectroscopic analysis. Detailed analysis
via high-performance liquid chromatography-mass spec-
trometry using electrospray ionization mass spectrometry
(ESI+-MS) [31] revealed three intense peaks in the base peak
chromatogram, withm/z = 1,435.8, 1,449.8, and 1,477.8, along
with corresponding doubly charged species (Figure S1 avail-
able online). MS/MS analysis of the doubly charged species
corresponding to the parent ion of 1,435.8 and 1,449.8 showed
fragmentation ions of m/z = 988.4, 1,080.5, and 1,102.5 (Fig-
ure S1). Similarly, MS/MS analysis of the parent ion of
1,477.8 showed fragmentation ions of m/z = 1,016.4, 1,108.6,
and 1,130.5 (Figure S1). These fragmentation patterns are
very characteristic of the well-known lipopeptides fengycin A
and fengycin B, which produce fragment ions representing
the lactone ring and the lactone ring with an attached ornithine
residue fragment (Figure 3B) [32].The mass spectrometric
results further indicated the presence of both carbon-14
(C-14) and carbon-15 (C-15) lipid chains in these lipopeptides.
Taken together, the purified antagonistic material contained a
mixture of C-14 fengycin A, C-15 fengycin A, andC-15 fengycin
B, among which C-15 fengycin A was most abundant.
To obtain direct evidence for the role of fengycin for the
observed phenotype, we generated a mutant defective in
fengycin production by disrupting one of the five open reading
frames of the fengycin (plipastatin) operon via a single
recombination event. The resulting ppsA mutant lost many
characteristics typically associated with lipopeptide produc-
tion (Figure S2). To test whether fengycin is involved in
B. thuringiensis DB27 inhibition, we tested the ppsA mutant
in bacterial inhibition assays. We found that the fengycin-
defective mutant exhibits significantly reduced antagonistic
activity against B. thuringiensis DB27 in the disc-diffusion
assay (Figure 4A) and confirmed this phenotype in coculture
experiments. Whereas the wild-type B. subtilis GS67 strain
completely eliminated B. thuringiensis DB27 after 24 hr of cul-
ture, the ppsA mutant was outcompeted by B. thuringiensis
DB27 (Figure 4B). These results indicate that the ppsAmutant
has lost the antagonistic properties against B. thuringiensis
DB27 and that the fengycins are the major inhibitory molecule
produced by B. subtilis GS67.
Next, we tested whether the fengycins are also required
for the protection of C. elegans against B. thuringiensis
DB27. We compared colonization of C. elegans intestines by
B. thuringiensis DB27 in worms grown on the ppsA mutant
and wild-type GS67. Indeed, worms grown on ppsA mutants
showed a much higher pathogen load in their guts compared
to GS67-grown worms (Figure 4C), which was not due to
the reduced ability of ppsA mutant to persist in C. elegans
intestine (Figure S2D). Also, we found that supernatant of
the ppsA mutant lost the ability to cure worms from
B. thuringiensis DB27 infection because ppsA-treated worms
exhibited survival similar to untreated controls (Figure 4D).
Finally, we grew worms on ppsA mutants and measured their
survival on the B. thuringiensis DB27 pathogen. Worms grown
on fengycin-defective mutants showed significantly reduced
survival on DB27 (Figure 4E) and S. aureus (Figure 4F)
compared to worms grown on wild-type B. subtilis GS67.
Thus, fengycin-mediated inhibition of pathogens is the mech-
anism of B. subtilis GS67-based C. elegans protection. We
Figure 4. Fengycin Mediates Protective Effects of B. subtilis GS67
(A) Representative image of disc-diffusion assay showing that ppsAmutant is strongly impaired in antagonism against DB27, as represented by a very small
zone of inhibition.
(legend continued on next page)
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2725also noticed a strong correlation between bacterial antago-
nism and nematode protection. Bacillus strains with strong
antagonistic activity against DB27 were also able to increase
C. elegans resistance to DB27, whereas none of the nonantag-
onistic strains showed the protective effect (Figure S3). Thus,
the strong correlation between antagonism and protection
suggests that this antagonism is the crucial mechanism
behind commensal-mediated C. elegans protection.
In the next set of experiments, we quantified the effect of
fengycin and tested the purified compound mixture for its pro-
tective effect on C. elegans. Specifically, we determined the
minimal inhibitory concentration (MIC) for the purified mixture
of fengycins using the broth dilution method. We found that
2.5 mg/ml was sufficient to inhibit DB27 growth. To assess
the viability of fengycin-treated DB27 cells, we applied LIVE/
DEAD staining and measured growth of DB27 in the presence
of fengycin. In contrast to viable control cells that stain green
(Figure 4G), most of the fengycin-treated cells stain red (Fig-
ure 4H), indicating they are not viable and have compromised
membranes. Consistent with this, fengycin exhibits a dose-
dependent lytic effect on DB27, as indicated by decline in op-
tical density (OD) (Figure 4I) and cfu (Figure S4A) values over
time. Finally, we prepared nematode growth medium (NGM)
plates with different concentrations of the purified mixture of
fengycins and used them to treat DB27-infected worms.
Indeed, fengycins rescue infectedworms in a dose-dependent
manner (Figure 4J). Whereas plates with the MIC showed only
a mild increase in survival, we found that at concentrations of
15 mg/ml, nearly 80% of worms survived (Figure 4J), indicating
that purified fengycins can cure infected worms directly.
Together, these results provide direct evidence for the role of
fengycin in C. elegans protection.
To test whether fengycin could also protect worms indirectly
via stimulation of an immune response, we first assessed by
quantitative PCR (qPCR) the expression of ten DB27-respon-
sive genes in worms treated with fengycin. DB27-responsive
genes were identified in a previous study analyzing the tran-
scriptional response of C. elegans after exposure to different
bacteria [5]. Five of these ten genes did not change their
expression, whereas the other five were even repressed
upon fengycin treatment (Figure S4B). Finally, immune-
compromised pmk-1 mutants still exhibited increased resis-
tance to DB27 after GS67 treatment (Figure S4C), suggesting
that GS67 protects worms independently of an immune
stimulation.
We have shown that replacement of E. coli OP50 with natu-
ral Bacillus strains can strongly increase C. elegans resistance
to pathogens. The strongest effect was observed forB. subtilis(B) ppsAmutant does not inhibit DB27 in coculture. When inoculated at equal
overgrown by DB27. Growth of ppsAmutant alone is comparable (p > 0.05) to
versus ppsA:DB27) reduced growth when cocultured with ppsA mutant. Error
(C) Colonization of C. elegans intestine is not affected by ppsAmutant (p > 0.0
GS67). Ten worms in three replicates were used for each tested group. Error b
(D) ppsAmutant does not cure worms that have the DB27 infection. Survival of
parable (p > 0.05) to untreated control worms. Shown are representative results
treatment).
(E and F) ppsAmutant lost protective properties against DB27 (E) and S. aureus
and S. aureus (F) comparable (p > 0.05) to control worms grown on OP50. Erro
(G andH) Representative images of DB27 cells either untreated (G) or treated (H)
Viable bacteria stain green; nonviable cells with compromised membranes sta
(I) Bactericidal effect of fengycin. Aliquots of DB27 culture (OD = 0.4) supplemen
OD600 values were used to measure the growth dynamic over time. See also F
(J) Purified fengycin cures DB27-infected worms.Worms infected (n = 20 in thre
with defined concentration of fengycin. Surviving worms, free of DB27 infection
0.05) compared to untreated control at 5 mg/ml, 10 mg/ml, and 15 mg/ml. ErrorGS67, which promoted C. elegans survival on B. thuringiensis
DB27 up to 3-fold but had no effect on resistance to Gram-
negative pathogens. Our study provides direct evidence for a
commensal-mediated mechanism of protection by antago-
nism of pathogens via antibiotic production, amechanism pre-
viously discussed in vertebrates [33, 34]. Combining chemical
and genetic analysis, we identified the lipopeptide fengycin, a
nonribosomally synthesized lipopeptide primarily known to
act against fungi [35, 36], to be responsible for the observed
antagonism. Fengycin-producing B. subtilis strains have
been applied in biological control of plant pathogenic fungi
[37], but the spectrum of activity and the exact mechanism
of action are not fully understood.
Bacteriocins and related lipopeptides have protective prop-
erties in other animal models as well. For example, it was
shown that a probiotic strain of Lactobacillus salivarius pro-
duces a bacteriocin in vivo, which can protect mice against
Listeria monocytogenes infection [38]. Similarly, plipastatin
(fengycin) was identified as the major B. subtilis molecule
responsible for S. aureus inhibition, and administration of fen-
gycin was shown to restrict growth of S. aureus onmurine skin
[39]. Therefore, bacteriocins and lipopeptides might be effec-
tive alternatives to classical antibiotics, given the growing
problem of antibiotic resistance. In addition, our results indi-
cate that C. elegans can be used as an in vivo model to reveal
protective mechanisms of commensal bacteria.
In conclusion, our work suggests that the commensal-medi-
atedB. subtilisGS67 protective effect onC. elegans is primarily
mediatedby its direct activity against the pathogen. This finding
highlights the importance of interspecies commensal-path-
ogen interplay for the outcome of C. elegans host-pathogen
interactions. Thus, the protective mechanisms of commensal
bacteria against C. elegans pathogens are more complex
than previously recognized and have to be taken into account
in studies addressing the defensive role of commensals.Experimental Procedures
Bacillus Feeding Assay
Each Bacillus strain tested was grown in a shaking incubator at 30C over-
night in lysogeny broth (LB), and 40 ml was spread on 6 cm NGM plates and
incubated overnight. C. elegans eggs obtained by bleaching were placed in
these NGM plates, with either Bacillus (experiment) or E. coli OP50 (control,
normal conditions). Plates were incubated at 25C until worms reached L4/
young adult stage and used in a pathogen survival assays.
Detection of Antagonistic Activity
The disc-diffusion assay was used for the test of antagonistic activities of
B. subtilis GS67 against other bacteria. Briefly, 50 ml of overnight culturesdoses, wild-type GS67 eliminates DB27 after 24 hr, whereas ppsAmutant is
the growth of GS67 and DB27. DB27 exhibits significantly (p < 0.0001, DB27
bars represent 6SEM.
5 OP50 versus ppsA) in contrast to wild-type GS67 (p < 0.0001 OP50 versus
ars represent 6SEM. See also Figure S2.
DB27-infected worms treated with the supernatant of ppsAmutant is com-
of at least two independent experiments (n = 50 in three replicates for each
(F) infections. Worms grown on ppsAmutant exhibited survival on DB27 (E)
r bars represent 6SEM.
with fengycin (15 mg/ml, 3 hr) and stainedwithBacLight bacterial viability kit.
in red. Scale bars represent 20 mm.
ted with defined doses of fengycin were incubated without shaking at 30C.
igure S4.
e replicates per treatment) with DB27 for 4 hr were transferred to NGMplates
, were scored 24 hr posttransfer. Curing effect of fengycin is significant (p <
bars represent 6SEM.
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2726of test bacteria with adjusted cell densities (OD = 1.0) was spread on 10 cm
LBplates. Paper discs (Whatman, 6mm)were placed on top of the agar, and
30 ml of the cell-free, filtered supernatant of B. subtilis GS67 grown for 48 hr
in LB at 30C was added to paper discs; LB was used as a negative control.
The plateswere incubated for 24 hr at 25C and examined for clear inhibition
zone around the discs. The experiment was done in triplicates and repeated
at least three times.
Mutant Strain Construction
An integrative plasmid was used to disrupt the production of fengycin. To
construct the plasmid pMut-ppsA, we PCR amplified a 1 kb fragment of
ppsA gene fromB. subtilisGS67 and ligated it into BamHI site of pMutin vec-
tor. To generate ppsA mutant, we transformed the wild-type strain
B. subtilis GS67 by electroporation with the pMut-ppsA plasmid. Positive
transformants were selected based on erythromycin resistance and were
molecularly confirmed using PCR and sequencing.
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and four figures and can be foundwith this article online at http://dx.doi.org/
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